NRP1 and neoplasm: Targeting the b1/b2 tandem domain of NRP1 with a monoclonal antibody results in a reduced density of the vascular network lacking associated pericytes, and delays tumor growth only in combination with anti-VEGF therapy, but is ineffective when used alone [107].